The week in pharma: action, reaction and insight – week to July 19, 2024

21 July 2024

By Barbara Obstoj-Cardwell. Editor

Last week, US healthcare giant Johnson & Johnson kicked off the second-quarter financial reporting period, posting better than expected results and raising its full-year forecast. The USA’s Biomedical Advanced Research and Development Authority (BARDA) recently announced that it has committed up to $500 million to fund next generation COVID vaccines. US biotech Caribou Biosciences said it is refocusing its research and cutting back its workforce. Also of note, Roche subsidiary Genentech terminated its collaboration with US precision medicines company Relay Therapeutics on migoprotafib.

J&J earnings: largely in Line as new products ready to offset Stelara biosimilars

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK